Postepy Dermatologii I Alergologii最新文献

{"title":"The influence of immune system-related genes on the development of atopic dermatitis.","authors":"Dominika Cieśla, Tomasz Nowak","doi":"10.5114/ada.2025.152114","DOIUrl":"https://doi.org/10.5114/ada.2025.152114","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a disease with a complex genetic background, in which only the predisposition to atopy is inherited. Genetic, environmental, and psychosomatic factors contribute to the development of this allergic inflammatory disease. The patient's age and population affiliation also play a significant role. Gene groups associated with AD are primarily: genes responsible for the epidermal barrier, interaction with the environment and related to the immune response. In turn, polymorphisms in these genes can affect the severity of atopic dermatitis through mechanisms such as excessive stimulation of the immune system or increased synthesis of immunoglobulin E (IgE). Among the genes related to the immune system that play an important role in the development of atopic dermatitis, we can distinguish: Chitinase-3-like protein 1 (<i>CHI3L1</i>), <i>FcεRI</i> (Fc epsilon RI, ligand-binding subunit of the high-affinity IgE receptor), toll-like receptors (<i>TLRs</i>), and cytokine encoding genes.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"232-242"},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Port-wine stain and its influence on patients' quality of life and psychosocial issues.","authors":"Klaudia Lipińska, Natalia Bień, Maria Rajczak, Michał Niedźwiedź, Paweł Kowalski, Aleksandra Kobusiewicz, Igor Bednarski, Małgorzata Skibińska, Joanna Narbutt, Anna Zalewska-Janowska, Dorota Sobolewska-Sztychny, Magdalena Ciążyńska, Aleksandra Lesiak","doi":"10.5114/ada.2025.152120","DOIUrl":"https://doi.org/10.5114/ada.2025.152120","url":null,"abstract":"<p><strong>Introduction: </strong>Port-wine stain (PWS) is a congenital vascular malformation. It can result in inferior quality of life or stigmatization. Multiple questionnaires are used to collect data about patients' mental state.</p><p><strong>Aim: </strong>The aim of the study was to investigate psychosocial well-being of patients with PWS using standardized tools and raise the awareness of the importance of mental health care in dermatological conditions.</p><p><strong>Material and methods: </strong>59 adult patients filled an online survey consisting of 5 psychological questionnaires: Dermatology Life Quality Index (DLQI), Skindex-29, Perceived Stigmatization Questionnaire (PSQ), Dysmorphic Concern Questionnaire (DCQ), Hospital Anxiety and Depression Scale (HADS), and also provided demographic data and lesion characteristics. The data were subjected to analysis.</p><p><strong>Results: </strong>Out of the 59 patients, 86.4% were females and 13.6% were males. The mean age was 32.12 years. According to DLQI, quality of life was decreased in 52.5% of patients. According to HADS, 45.8% of patients were affected by anxiety and 22% by depression. Skindex-29 revealed that PWS had a moderate negative influence on patients' life. In more than half of the patients, perception of their body was disturbed due to DCQ results.</p><p><strong>Conclusions: </strong>PWS affects psychosocial well-being of patients including their quality of life, self-perception of the body or feeling of stigmatization. Interdisciplinary approach is needed to provide patients with necessary psychological or psychiatric care.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"313-319"},"PeriodicalIF":1.4,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of refractory palmoplantar pustulosis using JAK-1 inhibitors and TYK-2 inhibitors: a real-world retrospective study.","authors":"Zeena Kailani, Rawan Aldahash, Mohannad Abu-Hilal","doi":"10.5114/ada.2025.152062","DOIUrl":"https://doi.org/10.5114/ada.2025.152062","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"320-321"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.","authors":"Yinyu Zhao, Chenxing Gao, Hong Leng","doi":"10.5114/ada.2025.152080","DOIUrl":"https://doi.org/10.5114/ada.2025.152080","url":null,"abstract":"<p><strong>Introduction: </strong>Prurigo nodularis (PN) is a chronic pruritic and inflammatory skin disorder and dupilumab is currently the only biologic agent approved in China for the treatment.</p><p><strong>Aim: </strong>To evaluate the efficacy and safety of dupilumab in managing moderate to severe PN through a retrospective study of 76 patients.</p><p><strong>Material and methods: </strong>A retrospective analysis was conducted of clinical and laboratory data from PN patients who received regular dupilumab treatment for 52 weeks at the Dermatology Department of the Second Affiliated Hospital of Soochow University between March 2021 and June 2023. Assessments were made at baseline (week 0), and at weeks 4, 8, 16, 26, and 52 using prurigo nodule counts, Investigator's Global Assessment (IGA) scores, Pruritus Numeric Rating Scale (NRS) scores, and Dermatology Life Quality Index (DLQI) scores to evaluate clinical symptoms and pruritus. Adverse events occurring post-treatment were also recorded to assess the drug's safety and efficacy.</p><p><strong>Results: </strong>A total of 76 patients with moderate to severe PN were included in this study. By week 52, there were significant reductions in prurigo nodule counts, IGA scores, NRS scores, and DLQI scores. Prurigo nodule counts decreased from a baseline of 74.64 ±33.45 to 2.3 ±0.9, IGA scores from 3.53 ±0.54 to 0.54 ±0.33, NRS scores from 7.65 ±2.27 to 1.01 ±0.65, and DLQI scores from 18.46 ±4.53 to 1.55 ±0.68, with all differences being statistically significant (<i>p</i> < 0.05). Seven patients experienced injection site reactions, and 2 patients developed facial erythema, which resolved either spontaneously or with symptomatic treatment. No other adverse events were reported.</p><p><strong>Conclusions: </strong>Dupilumab effectively reduces the number of PN, improves IGA scores, alleviates pruritus, and enhances quality of life in patients with moderate to severe PN, with a high safety profile.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"248-254"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of tuberculosis in psoriasis patients using anti-TNF therapy during 16 years of follow-up.","authors":"Ömer Mert, Begüm Güneş, Bahar Güler Filiz, Nahide Onsun","doi":"10.5114/ada.2025.152059","DOIUrl":"https://doi.org/10.5114/ada.2025.152059","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic multi-systemic inflammatory disease. Anti-tumor necrosis factor (TNF) agents such as adalimumab, infliximab, etanercept are effectively used for treatment. The increased risk of infection, especially tuberculosis is a major concern for patients receiving TNF inhibitor therapy.</p><p><strong>Aim: </strong>The aim of this study was to evaluate frequency and risk of tuberculosis in psoriasis patients using anti-TNF therapy over a 16-year period.</p><p><strong>Material and methods: </strong>This study is based on data from the Turkish Psoriasis Registry (PSR-TR) and digital records of the Medical School of the Bezmialem Vakif University. Patients with tuberculosis were recorded and the details of the treatment they received were explored.</p><p><strong>Results: </strong>We detected 3 patients with pulmonary tuberculosis and 1 patient with tuberculosis peritonitis in spite of isoniazid chemoprophylaxis. The common feature of these patients was a history of etanercept treatment.</p><p><strong>Conclusions: </strong>We concluded that psoriasis patients receiving TNF inhibitor therapy are at risk of tuberculosis infection despite isoniazid prophylaxis and contrary to the literature it looks like those patients treated with etanercept may be at greater risk for tuberculosis than patients treated with other TNF inhibitor agents.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"276-282"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-frequency ultrasound in the diagnosis of Hidradenitis suppurativa: experience from the Bulgarian HS Expert Centre.","authors":"Gavrail Poterov, Tanya Gancheva, Karen Manuelyan, Evgeniya Hristakieva","doi":"10.5114/ada.2025.151138","DOIUrl":"https://doi.org/10.5114/ada.2025.151138","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is an immune-mediated, autoinflammatory skin disease with different clinical manifestations. Traditional clinical examination may not assess HS true extent, while high-frequency ultrasound can detect subclinical lesions, influencing severity assessments.</p><p><strong>Aim: </strong>To compare the clinical severity of HS with the ultrasonography-based staging, and explore relationships between demographic data, risk factors and clinical phenotypes.</p><p><strong>Material and methods: </strong>An ongoing pilot study included 98 patients of the Bulgarian HS Expert Centre. Informed consent and epidemiological data were collected. Patients were categorized into disease duration groups (short/long) and classified by phenotype. Clinical severity was assessed through Hurley, IHS4, and HS-PGA staging systems and by ultrasound using SOS-HS, US IHS4, and US HS-PGA scales.</p><p><strong>Results: </strong>The study cohort was predominately male (74.5%) with a mean age of 36.69 years, average disease duration of 7.6 years and prevalence of the regular phenotype (53%). Age and disease duration correlated with Hurley stage (<i>p</i> < 0.05), but not with SOS-HS severity. Comorbidities correlated with disease duration (r = 0.256, <i>p</i> = 0.01), and the follicular-furunculous phenotype was associated with the females (<i>p</i> = 0.04). Clinical and ultrasound assessments showed strong correlations, although ultrasound showed higher severity scores (r = 0.42 to 0.92, <i>p</i> < 0.05), as well as significant differences across the phenotypes.</p><p><strong>Conclusions: </strong>HS is often underestimated due to delayed diagnosis and atypical presentations. Combining clinical and ultrasound assessments can provide more accurate staging. A multidisciplinary approach in expert centres can enhance diagnosis, treatment and monitoring.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"306-312"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of asthma-chronic obstructive pulmonary disease overlap phenotypes.","authors":"Özge Atik, Fatma Merve Tepetam, Şeyma Özden, Ayşe Ezgi Ak","doi":"10.5114/ada.2025.152082","DOIUrl":"https://doi.org/10.5114/ada.2025.152082","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma-chronic obstructive pulmonary disease overlap (ACO) patients are categorized as those with persistent airflow limitation and features of asthma and chronic obstructive pulmonary disease (COPD).</p><p><strong>Aim: </strong>This study aimed to identify ACO subgroups based on atopy, bronchodilator response (BDR), and eosinophil count.</p><p><strong>Material and methods: </strong>From 2021 to 2024, we conducted a retrospective study on patients with asthma and/or COPD who underwent BDR testing. An ACO diagnosis required persistent airflow limitation, a history of asthma before the age of 40 or significant BDR, and at least one minor criterion. Patients were grouped by atopy status, BDR presence, and eosinophil count. We compared demographic, laboratory, spirometry, and medication data across subgroups.</p><p><strong>Results: </strong>The study included 109 ACO patients with a mean age of 49.5 ±10.7 years. Atopic ACO patients showed a higher increase in FEV₁ after inhalation of 400 µg of salbutamol or the equivalent (ΔFEV₁BDR) and higher total IgE levels than non-atopic patients (200 ml vs. 100 ml, <i>p</i> = 0.034; 211 IU/ml vs. 60 IU/ml, <i>p</i> = 0.002). Eosinophil counts were higher in the BDR-positive group (360/µl vs. 195/µl, <i>p</i> = 0.047). High eosinophilic ACO patients also had elevated IgE levels (323 IU/ml vs. 80 IU/ml, <i>p</i> = 0.001). BDR-positive and eosinophilic groups demonstrated better spirometric results. Atopic ACO patients used more leukotriene receptor antagonists, while BDR-negative ACO patients used antimuscarinics.</p><p><strong>Conclusions: </strong>Higher ΔFEV₁BDR in atopic ACO indicates they may respond better to bronchodilators. Elevated eosinophil counts in BDR-positive patients support their classification and suggest less severe disease progression.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"283-290"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic polymorphisms of TIM-3 and its association with asthma in familial cluster asthma.","authors":"Sumanye Maolahong, Jun-Hui Chen, Xian-Tong Cai, Li Cong, Ying Chen, Zhi-Chuang Lian, Li-Ping Chen","doi":"10.5114/ada.2025.152152","DOIUrl":"https://doi.org/10.5114/ada.2025.152152","url":null,"abstract":"<p><strong>Introduction: </strong>TIM-3 gene polymorphisms strongly influence familial asthma susceptibility.</p><p><strong>Aim: </strong>This study investigates the genetic association of polymorphisms at rs9313441, rs511898, and rs953569 loci in the T cell immunoglobulin and mucin domain protein 3 (TIM-3) with familial asthma aggregation.</p><p><strong>Material and methods: </strong>Thirty asthma patients admitted to our hospital, diagnosed between December 2021 and December 2022, served as probands. We analysed three generations of direct blood relatives, dividing them into three groups (Generation I, II, III), each comprising 30 individuals. Data collected included demographic and high-risk asthma factors like gender, age, ethnicity, body mass index, and histories of asthma, allergies, and smoking. We compared these non-genetic factors across groups and conducted unilateral direct sequencing to determine allele and genotype frequencies at key loci.</p><p><strong>Results: </strong>The rs511898 locus showed no significant difference in the CC/CT genotype and allele distribution among the groups; however, the TT genotype was significantly more frequent in Generations I and II compared to Generation III (<i>p</i> < 0.05). At the rs953569 locus, the AA genotype was significantly more prevalent in Generation III than in the other groups (<i>p</i> < 0.05). The rs9313441 locus revealed a significantly higher frequency of the AG genotype in Generation III compared to the other two groups (<i>p</i> < 0.05), with no significant differences in GG and AA genotypes.</p><p><strong>Conclusions: </strong>There are distinct differences in TIM-3 gene expression across familial lines of asthma patients, and specific genotypes correlate with increased genetic susceptibility to asthma. Direct sequencing of these susceptibility genes aids in early identification and provides a foundation for targeted diagnosis, treatment, and preventive measures in familial asthma.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"267-275"},"PeriodicalIF":1.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid response to ixekizumab in a patient with erythrodermic psoriasis and drug-induced cirrhosis.","authors":"Delin Ran, Na Wang, Jing Liu, Peng Qu, Baoqi Yang","doi":"10.5114/ada.2025.149667","DOIUrl":"10.5114/ada.2025.149667","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 2","pages":"210-212"},"PeriodicalIF":1.4,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brivudine as a successful treatment for herpes zoster combined with chickenpox.","authors":"Yong Yao, Li Chen, Xianwei Cao, Hui Xiao, Jianbo Tong","doi":"10.5114/ada.2025.149542","DOIUrl":"https://doi.org/10.5114/ada.2025.149542","url":null,"abstract":"","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 3","pages":"322-324"},"PeriodicalIF":1.4,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}